• Crizocent 250mg: ALK Positive and ROS1 Lung Cancer Quick View
    • Crizocent 250mg: ALK Positive and ROS1 Lung Cancer Quick View

    • Crizocent 250mg: ALK Positive and ROS1 Lung Cancer

    • Crizocent 250mg (Crizotinib) is a highly effective targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase) or ROS1-positive. This innovative medication works by blocking the activity of proteins (ALK and ROS1) that promote cancer cell growth, making it an essential treatment for patients with these specific genetic mutations. Crizocent is trusted…
    • Read more